This Article Full Text Full Text (PDF) Other Versions of this Article: JCM.01299-07v1 46/1/274    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Guo, M. Articles by Sneige, N. Search for Related Content PubMed PubMed Citation Articles by Guo, M. Articles by Sneige, N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2008, p. 274-280, Vol. 46, No. 1
0095-1137/08/$08.00+0     doi:10.1128/JCM.01299-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Evaluation of a Commercialized In Situ Hybridization Assay for Detecting Human Papillomavirus DNA in Tissue Specimens from Patients with Cervical Intraepithelial Neoplasia and Cervical Carcinoma

Departments of Pathology,¹ of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas,² Department of Pathology, Taichung Veterans General Hospital, Taichung, Taiwan,³ Department of Obstetric/Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan⁴

Received 27 June 2007/ Returned for modification 15 September 2007/ Accepted 24 October 2007

To evaluate a commercialized in situ hybridization (ISH) assay for detecting human papillomavirus (HPV) DNA, we compared the ability of a new ISH probe, Inform HPV III (Ventana Medical Systems, Tucson, AZ), to that of PCR assays to detect HPV DNA in cervical tissue specimens with normal cervix (20 cases), cervical intraepithelial neoplasia (CIN; CIN 1, 27 cases; CIN 2, 28 cases; and CIN 3, 33 cases), and cervical carcinoma (29 cases). General HPV DNA was detected using consensus primer-mediated PCR assays. HPV genotyping was performed by using EasyChip HPV blot (King Car Yuan Shan Institute, I-Lan, Taiwan). HPV16 integration status (E2/E6 ratio) was determined by using quantitative real-time PCR. Our findings showed that the ISH and PCR had fair to good agreements in detecting HPV DNA across all CIN categories without significant differences (Kappa coefficient, 0.34 to 0.63; P = 0.13 to 1.0). However, ISH detected significantly fewer HPV-positive cases in carcinoma than PCR did (Kappa coefficient, 0.2; P = 0.03). Eleven cases with ISH^– PCR⁺ results had HPV types that can be detected by Inform HPV III. Five carcinoma cases with ISH^– PCR⁺ results showed a significantly higher level of integrated HPV16 (P = 0.008) than did the ISH⁺ cases. As a consequence, lower copy numbers of episomal HPV16 in carcinoma might be the cause for the false-negative ISH results. Although the punctate signal pattern of HPV significantly increased with the severity of disease (P trend = 0.01), no significant difference in the HPV16 integration status was observed between the cases with a punctate signal only and the cases with mixed punctate and diffuse signals (P = 0.4). In conclusion, ISH using the Inform HPV III probe seems comparable to PCR for detecting HPV DNA in cervical tissue with CINs. False-negative ISH results appear to be associated with the lower copy numbers of the episomal HPV16 but not with the ability of the Inform HPV III probe to detect specific HPV types. In addition, signal patterns, especially a mixed punctate and diffuse pattern of HPV, cannot be reliably used to predict viral integration status.

Published ahead of print on 31 October 2007.